Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01752855 · ClinicalTrials.gov registry record · Phase 2

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

A Phase 2 study of Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT01752855: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott).

NCT01752855 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 88 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01752855, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.

Primary Outcome

The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • BIOLOGICAL New formulation adalimumab

Study Locations (20)

Other

  • Site Reference ID/Investigator# 92053 - Brussels
  • Site Reference ID/Investigator# 92054 - Liège
  • Site Reference ID/Investigator# 91954 - Brno
  • Site Reference ID/Investigator# 91955 - Prague
  • Site Reference ID/Investigator# 91953 - Uherské Hradiště
  • Site Reference ID/Investigator# 91956 - Zlín
  • Site Reference ID/Investigator# 92073 - Ratingen
  • Site Reference ID/Investigator# 92074 - Vega Baja
  • Site Reference ID/Investigator# 92093 - Bucharest
  • Site Reference ID/Investigator# 92095 - Cluj-Napoca
  • Site Reference ID/Investigator# 92094 - Ploieşti
  • Site Reference ID/Investigator# 92096 - Banská Bystrica
  • Site Reference ID/Investigator# 92097 - Senica
  • Site Reference ID/Investigator# 92098 - Žilina

Arizona

  • Site Reference ID/Investigator# 92113 - Mesa

California

  • Site Reference ID/Investigator# 92118 - Hemet

Kansas

  • Site Reference ID/Investigator# 92117 - Wichita

New Jersey

  • Site Reference ID/Investigator# 92115 - Clifton

Pennsylvania

  • Site Reference ID/Investigator# 92116 - Philadelphia

South Carolina

  • Site Reference ID/Investigator# 92114 - Charleston

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2012-12
Est. Completion 2013-10
Phase Phase 2
AbbVie (prior sponsor, Abbott)

88 total trials

What the finished NCT01752855 record still lists

NCT01752855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which New formulation adalimumab is the first listed.

NCT01752855 names 20 study sites across 7 states, led by Other, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT01752855 about?

NCT01752855 is a clinical study titled "Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab". A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.

What is the current status of trial NCT01752855?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2012-12. Estimated completion is 2013-10.

What conditions does trial NCT01752855 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01752855?

The interventions under investigation include: New formulation adalimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT01752855?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01752855 being conducted?

This trial has 20 study locations across Arizona, California, Kansas, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01752855's enrollment target sits among peer trials

88 121st of 197 higher than 77 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01752855, the US trial registry maintained by the National Library of Medicine. NCT01752855 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.